Market revenue in 2021 | USD 45.4 billion |
Market revenue in 2030 | USD 68.9 billion |
Growth rate | 4.7% (CAGR from 2021 to 2030) |
Largest segment | Anti-hypertensive |
Fastest growing segment | Hormones |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2030 |
Quantitative units | Revenue in USD billion |
Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 15.64% in 2021. Horizon Databook has segmented the North America branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
Growth of North America branded generic market can be attributed to various factors, such presence of major market players & well-developed infrastructure, rise in prevalence of various diseases in the region, and favorable government initiatives that support the uptake of branded generics.
Furthermore, increasing awareness pertaining to highly potent drugs, rising demand for anti-cancer therapeutics, and growing number of pharmaceutical companies are some of the factors contributing to the high share held by this regional market.
Increase in regulatory support and rise in investments in biotechnology & pharmaceutical industries are anticipated to fuel market growth. Moreover, blockbuster and patented drugs nearing expiration provide key opportunities to companies for revenue generation by manufacture and sale of branded generics.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America branded generics market , including forecasts for subscribers. This continent databook contains high-level insights into North America branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account